VANCOUVER, British Columbia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (“Vergence”). The launch is anticipated to take place on Cyber Monday and the new product line will be the first of twelve products the Company hopes to launch over a 36-month period.
“We are very proud to have developed two products that safely reduce pain and modulate inflammation. Searches for pain remedies are among the top cannabis-related searches on Amazon.com and Google and we are confident that our products will be well received by the growing number of consumers interested in cannabinoid-based therapies for pain and inflammation,” stated Dr. Brazos Minshew MSc, ND, President of the Abattis Medical Advisory Board.
“Developing an effective formula was only the beginning, however. We have also secured a consistent supply of the ingredients on which our products will be based, including the rare phytocannabinoid, Alpinia galangal,” added Dr. Minshew. Alpinia galanga is commonly found in Indonesia and Malaysia and has historically been used to relieve gastric distress. More recently, it has been used to improve mental alertness and attention and has also been combined with cisplatin to treat lung cancer. More relevant to our applications, Alpinia galanga also binds to and activates both CB1 and CB2, the body’s main cannabinoid receptors. By activating these receptors, Alpinia galanga reduces pain and inflammation and improves mobility.
Through Vergence, the Company plans a substantial direct response marketing campaign to increase awareness of the benefits of phytocannabinoid products from Vergence. “We are planning for our campaign to launch on Cyber-Monday (November 26, 2018) and to include 25,200+ localized airings in every major U.S. city to a total of over 110 million households,” stated Rob Abenante, President and CEO of Abattis. The Company will provide further details respecting the upcoming marketing campaign and product launch in subsequent news releases.
About Abattis Bioceuticals Corp.
Abattis is a leading diversified cannabis company, with interests in operations engaged in growing, extraction, testing, propagation and retail distribution. Over the past year, Abattis has made key acquisitions to leverage synergies and vertically integrate its business. Through its partnership with Northern Vine Labs and its investment in XLABS Therapeutics (ONT) Inc., Abattis has access to a fully licenced laboratory facility and an industrial size laboratory currently in the process of obtaining a Health Canada dealer’s license and, through its wholly owned subsidiary Gabriola Green Farms, it has applied for a Health Canada license to produce and sell Cannabis flower and oils. Abattis also operates a retail vaporizers business through its wholly owned subsidiary, Green Tree Therapeutics, which offers 10 unique branded SKUs online and across the country and owns a series of marketing, licensing and technology rights. Abattis has also partnered with a number of organizations, including the University of British Columbia Faculty of Land and Food Systems, with which it is developing delivery platforms with increased stability and bioavailability for cannabinoid rich THC-free hemp extracts. For more information, visit the Company’s website at: www.abattis.com
ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,
"Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at (604) 441-1304 or at investors@abattis.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the Company’s plans to launch a new line of products to alleviate pain and inflammation on Cyber Monday; the Company’s plans to launch twelve new products over the next 36 months; the Company’s belief that its products will be well received by the growing number of consumers interested in cannabinoid-based therapies for pain and inflammation; and the Company’s plans for its direct response marketing campaign. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the Company will not launch its new line of products to alleviate pain and inflammation or that such launch will not take place on Cyber Monday; that the Company will not launch twelve new products over the next 36 months; that the Company’s products will not be well received by the growing number of consumers interested in cannabinoid-based therapies for pain and inflammation; that the Company’s direct response marketing campaign will not take place as expected; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.